ASH 2023 | 28-day vs 14-day ven plus aza in older patients with newly diagnosed AML
Uma Borate, MD, The Ohio State University, Columbus, OH, introduces a sub-study of the Beat AML Master Trial (NCT03013998), which will aim to compare an FDA standard 28-day venetoclax (ven) plus azacitidine (aza) regimen, with a 14-day ven-aza regimen, in patients over 60 years of age with newly diagnosed acute myeloid leukemia (AML). Dr Borate hopes that this randomized Phase II trial will show comparable efficacy of the shorter regimen, with decreased toxicity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: Astellas, Blueprint, Novartis, Kura, Takeda, Agios, Genentech, Servier, Abbvie
Honoraria: RUNX1 Foundation
Research Funding: Pfizer, Abbvie, Jazz
Other: Incyte
